WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentATAZANAVIRRITONAVIR - Not to be coadministered with omeprazole
Afficher le documentCELECOXIB - Increased risk of cardiovascular events
Afficher le documentDARBEPOETIN ALFA - Adverse outcomes associated with off-label dosing strategies
Afficher le documentGALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment
Afficher le documentGLUCOSAMINE - Concerns about hypercholesterolaemic effects
Afficher le documentNAPROXEN - Long-term study indicates cardiovascular risk
Afficher le documentNEVIRAPINE - Not recommended in women with CD4+ cell counts greater than 250 cells/mm3
Afficher le documentPROPOFOL - Adverse events with both low- and high-rate infusions
Afficher le documentROSUVASTATIN - More reports of rhabdomyolysis
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE

GALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment

Canada. Janssen-Ortho Inc., under advice from Health Canada, is warning health professionals that according to preliminary data from two investigational studies, galantamine (Reminyl), a cholinesterase inhibitor, does not appear to be effective in treating patients with mild cognitive impairment (MCI). In addition, the initial analysis of both studies showed that 15 patients died in the galantamine (Reminyl) treatment group and five in the placebo treated group. The causes of death were mainly cardiovascular or cerebrovascular in nature.

Janssen-Ortho is reminding that galantamine (Reminyl) is approved only for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type and that it is not to be used outside of its approved indication.


'Dear Health-care Professional' letter from Janssen-Ortho Inc., 21 January 2005. Available on the Internet at www.hc-sc.gc.ca

vers la section précédente
vers la section suivante
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 29 octobre 2018